Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Oncology Inc. (NasdaqGS: RAIN) is a clinical-stage biotechnology company developing precision therapies targeting specific cancer drivers. This news hub provides investors and researchers with timely updates on the company's progress in oncology innovation, including its lead candidate milademetan and strategic initiatives.
Access authoritative updates on clinical trial developments, regulatory milestones, and corporate announcements. The resource consolidates essential information about RAIN's therapeutic pipeline, financial position, and partnership activities – critical data points for evaluating the company's trajectory in precision medicine.
Key coverage areas include progress in Phase 3 MANTRA trials for liposarcoma, updates on tumor-agnostic basket studies, and analysis of strategic merger plans with Pathos AI. All content maintains rigorous standards for accuracy and clarity, serving both professional investors and those monitoring advancements in cancer treatment.
Bookmark this page for direct access to verified Rain Oncology announcements and objective reporting on developments impacting the company's scientific and financial progress.
Rain Therapeutics reported a net loss of $18.4 million for Q3 2021 and $33.4 million for the first nine months, compared to losses of $10.4 million and $15.6 million in the same periods of 2020. The company ended Q3 with $150.1 million in cash, providing a runway to advance clinical trials, including the MANTRA-3 trial for milademetan in Merkel cell carcinoma, set to start in mid-2022. R&D expenses rose to $15.3 million for Q3 2021, up from $7.9 million in Q3 2020. Milademetan shows promise in ongoing and upcoming trials, aiming for significant oncology advancements.
Rain Therapeutics (NASDAQ: RAIN) has announced the initiation of the MANTRA-3 Phase 2 clinical trial for milademetan as a treatment for Merkel cell carcinoma (MCC) in patients who are resistant to immunotherapy. The trial, set to start mid-2022, will enroll approximately 30 patients. The primary objective is to assess the objective response rate through RECIST criteria. This move comes after promising preclinical results and replaces a previously planned trial for intimal sarcoma. Rain will also host its first annual R&D Day webinar today to discuss relevant oncology research.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to report its Q3 financial results for the period ending September 30, 2021, on November 10, 2021. The company will also highlight recent advancements in precision oncology therapeutics during a conference call at 1:30 p.m. PT (4:30 p.m. ET). Rain focuses on developing therapies targeting oncogenic drivers through a tumor-agnostic strategy, with its lead candidate milademetan (RAIN-32) being an oral MDM2 inhibitor. Investors can access a recorded version of the call on the company’s website for 30 days.
Rain Therapeutics Inc. (NasdaqGS: RAIN) will host a virtual Research and Development (R&D) day on November 9, 2021, featuring prominent oncology experts discussing milademetan, a precision oncology therapy targeting MDM2-mediated p53 loss. CEO Avanish Vellanki expressed excitement to share updates on the drug's potential in various cancer populations. Key opinion leaders will present findings related to ER+ breast cancer, Merkel cell carcinoma, and liposarcoma, among others. The event will also include management insights and Q&A sessions.
Rain Therapeutics presented promising data on its MDM2 inhibitor, milademetan, at the 2021 AACR-NCI-EORTC conference. The findings suggest significant anti-tumor activity in genetically selected models including advanced cancers with MDM2 amplification, and GATA3 mutant ER-positive breast cancer. Notably, milademetan showed the potential to treat Merkel cell carcinoma and ER+ breast cancer that are resistant to current therapies. The company is ongoing with Phase 3 trials for liposarcoma and plans a Phase 2 tumor-agnostic trial.
Rain Therapeutics has announced its participation in the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The company will present three posters on its MDM2 inhibitor, milademetan, highlighting its potential as a therapeutic target. Notable presentations include the predictive biomarker for milademetan and its effectiveness in various cancers. Furthermore, Rain will host an R&D day webinar on November 9, 2021, at 11:00 am ET, discussing ongoing research and key data.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is scheduled to present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO Avanish Vellanki will lead the presentation on September 30, 2021, at 10:00 a.m. ET, which can be accessed via a webcast link or through Rain's website. The event aims to showcase Rain’s advancements in precision oncology therapeutics, including their lead product candidate, milademetan, a small molecule oral inhibitor targeting MDM2. A replay will be available on their website for 30 days after the event.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Vellanki's presentation is scheduled for September 13 at 7:00 a.m. ET. Interested parties can access the presentation via a webcast link or through the Rain website. A replay will be available for 30 days post-event. Rain focuses on precision oncology, developing therapies like milademetan, a small molecule MDM2 inhibitor, targeting various cancers.
Rain Therapeutics announced promising non-clinical data on its oral MDM2 inhibitor, milademetan (RAIN-32), at the IASLC 2021 World Conference on Lung Cancer. The findings indicate that milademetan treatment effectively targets malignant pleural mesothelioma (MPM), showcasing differential sensitivity based on genetic profiles. Increased p53 protein levels were noted in sensitive cell lines, and significant growth reduction was observed in MPM xenografts. Rain aims to address the unmet medical needs of MPM patients, particularly post anti-PD1 therapy.
Rain Therapeutics Inc. (NASDAQ: RAIN), a late-stage precision oncology firm, is presenting at the IASLC 2021 World Conference on Lung Cancer from September 8-14, 2021. The poster, titled The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma, will be presented by Dr. Lynn Heasley on September 8. Additionally, Avanish Vellanki will participate in a Targeted Oncology Panel at the Citi 16th Annual Biopharma Conference on September 10. Recordings will be available on the Rain website post-event.
FAQ
What is the current stock price of Rain Enhancement (RAIN)?
What is the market cap of Rain Enhancement (RAIN)?
